Skip to content

Study · Non-randomized trial · n = 10 · 1995

2 results

Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly.

Giustina A, Bresciani E, Bugari G, Bussi AR, Deghenghi R, Imbimbo B, Giustina G

Endocrine research1 Aug 1995Cited by 1 (Europe PMC)

PMID7588427 (opens in a new tab)DOI10.1080/07435809509030474 (opens in a new tab)PepBankPUB-07588427
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with active acromegaly, a hexarelin bolus raised the mean GH peak by 1750% from baseline.

    In plain wordsIn people with active acromegaly, a single hexarelin dose strongly raised growth hormone above baseline.

    Peptide
    Hexarelin
    Outcome
    IncreaseMean GH peak after hexarelin alone
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous · single bolusAs given in this study (human).

    Measurements

    Mean GH peak, change from baseline
    1750%
    hexarelin alone

    Source sentences

    Summary
    The mean GH peak, expressed as percent change with respect to baseline level (mean of -75 and -60 minute samples), after hexarelin (1750 +/- 1157%)
    2 context sentences
    Summary · context
    Ten patients (5 males, 5 females; age range 27-71 years; BMI range 23.3-35 kg/m2) with active acromegaly
    Summary · context
    The aim of our study was to ascertain whether hexarelin was able to counteract the glucocorticoid-mediated increase in hypothalamic somatostatin tone and consequent inhibition on serum GH levels in acromegalic patients.

Studies that did not test the peptide alone1

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 02HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome

    In patients with acromegaly, the GH peak after hexarelin plus hydrocortisone did not differ significantly from the peak after hexarelin alone.

    In plain wordsIn people with acromegaly, adding hydrocortisone did not significantly change the growth hormone peak after hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH peak after hexarelin plus hydrocortisone versus hexarelin alone
    Study

    n = 10

    Comparator
    Hexarelin alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean GH peak, hexarelin alone
    1750 % change from baseline
    hexarelin
    Mean GH peak, hexarelin plus hydrocortisone
    1120 % change from baseline
    hexarelin plus hydrocortisone

    Source sentences

    Summary
    The mean GH peak, expressed as percent change with respect to baseline level (mean of -75 and -60 minute samples), after hexarelin (1750 +/- 1157%) did not differ significantly with respect to that observed after hexarelin+hydrocortisone (1120 +/- 770%).
    2 context sentences
    Summary · context
    Ten patients (5 males, 5 females; age range 27-71 years; BMI range 23.3-35 kg/m2) with active acromegaly
    Summary · context
    The aim of our study was to ascertain whether hexarelin was able to counteract the glucocorticoid-mediated increase in hypothalamic somatostatin tone and consequent inhibition on serum GH levels in acromegalic patients.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.